The survival of patients with renal cell carcinoma (RCC) has improved in recent years. However, data on the risk of developing a second cancer after a diagnosis of RCC is limited. We used the data available in the Surveillance Epidemiology and End Results (SEER) database to estimate the risk of second metachronous primary cancers in patients diagnosed with RCC between 1973 and 2006. Furthermore, we also investigated the effect of the second primary cancers (SPCs) on the survival of RCC patients.
M alignancies of the kidney (including the renal pelvis) are the seventh and eighth leading cause of cancer among men and women in the United States, respectively. They are also among the top 10 causes of cancer-related deaths among men in the country. 1 Globally, they are more common in developed rather than developing countries and in male individuals rather than female individuals. 2 About 85% of all kidney cancers arise from the renal parenchyma (termed as renal cell carcinomas or RCCs), whereas the remaining arise from the urothelium lining the renal pelvis. 3 It is estimated that nearly 58,240 cancers of the kidney and renal pelvis were diagnosed in the United States in 2010, and about 13,040 patients died from these malignancies in the same period. Male individuals accounted for more than 61% of all newly diagnosed cases and about 63% of all deaths from the malignancy. 1 An interesting statistic is that there are an estimated 148,840 survivors of kidney and renal pelvis cancers in the United States alone. 4 The growing population of cancer survivors (both in case of RCC and other malignancies) has resulted in the emergence of a new area of cancer research, that is, the study of second primaries arising in patients with an existing malignancy. Understanding the epidemiology of second primary cancers (SPCs) is an important first step in studying the molecular and genetic mechanisms underlying their development.
According to the National Cancer Institute, a SPC is defined as a new primary malignancy that occurs in a patient with a prior history of cancer (www.cancer.gov). Metachronous SPCs (ie, SPCs that were diagnosed after a certain period of time after diagnosis of the first primary cancer) have been reported in association with several malignancies including male breast cancer, 5 colon cancer, 6 gastric cancer, 7 esophageal cancer, and other head and neck cancers. 8, 9 In some of these malignancies, SPCs have also been reported to influence survival. For instance, patients with squamous cell carcinoma of the head and neck who developed a SPC had a 24% lower mortality after 15 years compared with those who did not develop a second tumor. 10 Liu et al 11 reported that patients who developed a lung cancer first followed by a SPC had a significantly longer median survival than patients who had a nonlung primary tumor followed by a SPC in the lungs. Data on the incidence of SPCs in patients with a prior diagnosis of RCC, however, are very limited, restricted only to a few European studies. One population-based study in Norway for instance noted that the incidence of multiple primary malignancies in patients with a prior diagnosis of RCC was nearly 47%. 12 Other smaller studies have reported that between 16% and 18.5% of RCC patients develop a second primary malignancy. 13, 14 Given that newer treatments are improving survival of patients with RCC, 15, 16 understanding the incidence and prognostic significance of SPCs in RCC survivors becomes an important question, both from the perspective of cancer treatment and the quality of life of the patient. Hence, the aim of this study was to investigate the risk of second malignancies in patients with RCC using data from the Surveillance Epidemiology and End Results (SEER) database. Furthermore, we also sought to examine the effect of SPCs on the survival of RCC patients.
METHODS

Population Selection
The SEER database (9 registries limited use, updated: November 2008) was queried for patients with RCC (ICD code: 8312/3) who were diagnosed between January 1973 and December 2006 with RCC and a SPC. Only cases in which RCC was the first of 2 or more cancers were considered for the analysis. Patients in whom the diagnosis of RCC was made at autopsy or mentioned in the death certificate only were excluded as were any SPCs diagnosed within 1 month after the detection of RCC. Deidentified information about individual patients with either RCC alone or RCC with SPC was also obtained from the SEER database (17 registries limited use, updated November 2008, containing information of cases between 1973 and 2006) and was used to analyze the effect of SPCs on survival of RCC patients and the effect of individual factors on the survival of RCC patients with SPCs.
Statistical Analysis
Statistical analysis was performed using the PASW Statistics 18 software program (Release 18.0, SPSS Inc, IL). The SEER*Stat version 6.5.2 was used to stratify the cases by age, sex, race, radiation therapy, site of SPC, and latency period and to obtain the deidentified information about individual cases. The risk of an SPC was calculated by determining the standardized incidence ratio (SIR), which is defined as the ratio of the numbers of observed cases (O) of subsequent primary cancers (ie, second, third etc.) at a given site (in patients with a preexisting primary cancer) to the number of expected (E) subsequent cancers at the same site in the general population. Age, size of the primary RCC, and the time elapsed between RCC and the second primary were considered as continuous variables, whereas sex, race, marital status, stage, grade and laterality of RCC, history of radiation therapy, and history of radiation sequence with surgery were considered as categorical variables. A 2-tailed Student t test was used to compare the mean values for continuous variables. Z test was applied to compare the proportion of patients between 2 categories. Kaplan-Meier survival analysis was used to examine the effect of individual risk factors on the overall survival (OS) of patients. A Cox proportional hazards test was used for multivariate analysis of factors affecting survival. All tests were conducted with 95% confidence intervals (CI). A P value of <0.05 was considered significant.
RESULTS
Study Population
A total of 3795 patients with RCC who were subsequently diagnosed with 1 or more SPCs were registered in the multiple primary SIR section of the SEER database (comprising information from 9 registries in the United States) between 1973 and 2006. The expected number of SPCs in the population during the same period was estimated to be 3208. Thus, the ratio of observed to expected number of second primaries (ie, the SIR) was 1.18 (95% CI 1.15-1.22), which was significantly higher than expected (P < 0.05).
Solid tumors were the most common type of second malignancy in patients with RCC, accounting for over 90% of all SPCs. About 8% of second malignancies arose in the lymphatic and hematopoietic system and in about 2% cases the sites did not fit either classification. The most common sites of occurrence of second malignancies in RCC patients were the male genital system (n = 896, 23.6%), the digestive system (n = 718, 18.9%), and the respiratory system (n = 562, 14.8%) ( Table 1) .
Relationship of Patient and Tumor-related Factors on the Risk of SPCs in RCC
We first sought to investigate whether patient and/or tumorrelated factors had an effect on the risk of SPCs in patients with RCC. For this, the risk of SPCs was estimated from the actual number of second primaries reported during a follow-up period of >20 years (range, 1 mo to >20 y) from the time of diagnosis of RCC. Two types of risks were examined: (a) risk of a second cancer at all sites combined (termed as "overall risk") and (b) risk of a second cancer at a specific site (termed as "site-specific risk"). The following factors were investigated.
Age at Diagnosis of RCC
Patients with RCC followed by a second cancer were divided into 3 groups based on their age at the time of diagnosis of the RCC: <30 years, 30 to 59 years, and Z60 years. As shown in Table 1 , the overall risk of SPCs was significantly increased in all 3 age groups with patients younger than 30 years nearly 4 times more likely to develop a second malignancy than their older counterparts.
Analysis of the risk at specific sites revealed that in patients older than 30 years, the risk of a SPC was highest in the kidney (SIR: 170). Among hematologic malignancies, the risk was highest (23-fold) for non-Hodgkin lymphoma. For patients between 30 and 59 years old, the risk was highest for acute monocytic leukemia (SIR: 7.3) followed by colon and thyroid cancer (SIR: 2.4 and 3.5, respectively). Among patients aged 60 years or more, the risk of a second malignancy was highest in the endocrine glands, particularly in the thyroid (SIR: 27) and adrenal glands (SIR: 7).
Age Attained at the Time of Detection of the SPC
We next investigated whether the age attained by the patient at the time of detection of the second cancer had an effect on their risk of developing the second malignancy at a specific site.
Only 5 RCC patients were younger than 30 years at the time of their second malignancy and all were diagnosed with a second primary in the kidney. This translated into a >1000fold higher risk of developing SPCs in the kidney (Table 1) .
Among patients aged 30 to 59 years, the risk of a SPC was highest in the kidney (SIR: 13.6) followed by the thyroid gland and liver (SIR: 4.5 and 2.6, respectively).
Patients 60 years or older at the time of diagnosis of the second primary were at the highest risk of a second malignancy in the endocrine system, specifically in the thyroid and adrenal glands (SIR: 3 and 6.6, respectively).
Race
The overall risk of a second cancer was significantly increased in whites and blacks but not in other racial groups ( Table 2 ). The risk was higher in blacks compared with whites (SIR: 1.38 vs. 1.15, respectively). The adrenal gland was the site with the highest risk of a second malignancy among whites (SIR: 7.3), whereas the kidney, thyroid gland, small intestine, and colon were at the highest risk of a second primary among blacks (SIR: 9.9, 4.7, 3.4, and 3, respectively). Of note, the risk of a second cancer in the kidney, prostate, urinary bladder, and the thyroid gland were increased in all racial groups.
Sex
Although the overall risk of second malignancies was similar in both male and female individuals (SIR: 1.2), it was significantly elevated only in the former. Significantly, male individuals had a statistically higher risk of solid cancers whereas the risk of hematologic malignancies was significantly elevated in female individuals. In male individuals, the risk of a second primary was highest in the adrenal glands (SIR: 6.6) followed by the kidneys and thyroid gland (SIR: 4.4 and 3.4, respectively) ( Table 3 ). In female individuals, the risk of a second malignancy was highest in the kidneys (SIR: 5.6) followed by the thyroid gland (SIR: 3.2). Significantly, the risk of a second cancer in both the sexes was highest in the first 6 months after the diagnosis of RCC but declined thereafter ( Supplementary Tables 1 and 2 
Size of the Kidney Tumor
We next examined whether there was a relationship between the size of the first primary cancer (ie, RCC) and the risk of a second malignancy at a specific site. For this, the RCC patients were divided into 3 groups based on the maximum diameter of the renal tumor: <5 cm, between 5 and 10 cm and Z10 cm. As shown in Table 3 , the risk of a second malignancy was significant in cases for renal tumors <10 cm in diameter, but not for larger tumors. For tumors <10 cm in size, the risk of a second malignancy was highest in the kidneys (SIR: 5) and endocrine glands (SIR: 3.8 to 4.1), particularly in the thyroid gland and adrenals. Interestingly, the risk of a second malignancy in the urinary bladder and prostate was strongly increased within the first 6 months after diagnosis of RCC, with a decline thereafter (Supplementary Tables 3 and 4 ; Supplemental Digital Content 3, http://links.lww.com/AJCO/A7 and Supplemental Digital Content 4, http://links.lww.com/AJCO/ A8). Among hematologic malignancies, the risk of lymphocytic leukemias, specifically chronic lymphocytic leukemia was significantly elevated (SIR: 1.94) only for tumors <5 cm in diameter but not for larger tumors. The only site with a sig-nificant risk of a second malignancy for tumors Z10 cm in size was the kidney (SIR: 5.3).
History of Radiation Therapy
Therapeutic radiation is well known to increase the risk of cancers in general. [17] [18] [19] We sought to investigate whether RCC patients who received radiation therapy had a difference in the risk of a second malignancy compared with those who had not received any form of radiation (including radioisotopes) therapy.
We found that the overall risk of a second malignancy was slightly higher in those patients who had not received radiation therapy compared with those who did (SIR: 1.18 and 1.11, respectively). The increased risk extended to both solid and hematologic malignancies in the former as summarized in Table 3 . Among patients who received radiation therapy, the sites with the highest risk of a second malignancy were the radiation (SIR: 3.1). Conversely, the sites with an increased risk of a second malignancy specific to those who did not receive radiation were the skin and urinary bladder (SIR: 1.2 each).
Prognostic Significance of SPCs in RCC
Having determined the sites with a differential risk of a second malignancy, we next sought to investigate the effect of second malignancies on the survival of RCC patients.
For this, we retrieved deidentified information on all RCC patients registered with the SEER database. A total of 58,174 patients with RCC were registered in 17 registries of the SEER database. Of these, 42,314 (72.7%) patients had RCC as the only primary tumor. This group was designated as "only primary cancer (OPC). In 5769 cases (9.9%), RCC was the first of 2 or more primary malignancies. This group was designated as "SPC." In the remaining cases, RCC was diagnosed as the third or later of multiple primary cancers. Comparison of demographic characteristics of patients belonging to the OPC or SPC group (summarized in Supplementary Table 7 ; Supplemental Digital Content 7, http://links.lww.com/AJCO/A11) revealed that SPC patients were significantly older at the time of diagnosis and were more likely to be male individuals, black, and married, and less likely to have received radiation compared with the OPC group.
To determine the prognostic significance of SPCs in RCC, we first analyzed the effect of patient and tumor-related factors (including presence of second primaries) on the OS of patients (with RCC ± SPC) by the Kaplan-Meier method. As shown in Figure 1 and summarized in Table 4 , patients in the SPC group had a significantly better survival than those in the OPC group. The other factors that predicted a longer OS in RCC patients included aged 60 years or older at the time of diagnosis of RCC, nonwhite nonblack race, female sex, marital status (married/single), a well-differentiated, localized, unilaterlal renal tumor r5 cm in diameter, and the absence of radiation therapy (with/without subsequent surgery) ( Supplementary Fig. 1 ; Supplemental Digital Content 10, http://links.lww.com/AJCO/A14).
Upon multivariate analysis, age <60 years at the time of diagnosis of RCC, female sex, married status, localized stage, well or moderate degree of differentiation (of RCC), tumor size r5 cm, absence of radiation therapy, and an unilateral RCC were significant independent predictors of a longer OS ( Table 5 ). Presence of SPCs and race, however, were not retained as significant predictors of OS in the multivariate analysis.
Factors Influencing Prognosis of RCC Patients With 1 or More SPCs
Patients with multiple primary malignancies may be affected by prognostic factors unique from those with single primary cancers. Hence, we also investigated the factors that influence the OS of patients with RCC and one/more second cancers.
As summarized in Table 6 and illustrated in Supplementary Figure 2 , (Supplemental Digital Content 11, http:// links.lww.com/AJCO/A15) age <60 years at the time of diagnosis of either RCC or the second malignancy, white or nonwhite or nonblack race, married status, a localized, welldifferentiated, right sided renal tumor, lack of a history of radiation and an interval of Z60 months between diagnosis of RCC and the second malignancy were associated with longer OS in patients with RCC and one/more second malignancies. Sex of the patient and size of the primary renal tumor, however, did not affect the OS significantly.
Upon multivariate analysis (Table 7) , only age <60 years at the time of diagnosis of the SPC, lack of a history of radiation therapy and an interval of Z1 year between the diagnosis of RCC, and the second malignancy were significant predictors of longer survival in RCC patients with second malignancies.
DISCUSSION
This study represents the first comprehensive analysis of the risk of SPCs in patients diagnosed with RCC from data available in the SEER database. We observed that about 10% of all patients with RCC had one or more new primary tumors. The largest number of second cancers arose in the male genital system (particularly the prostate gland) and in the digestive and respiratory system. The overall risk of a second malignancy was highest in patients <30 years old at the time of diagnosis of either RCC or the second primary malignancy. Furthermore, patients with a second cancer had a significantly longer OS than those without a second malignancy.
The incidence of second cancers among RCC patients reported in our study is much lower than that reported in other non-US populations. For instance, a study by Beisland et al 12 in Norway had reported that the incidence of second malignancies in RCC was 47%. Other studies have reported an incidence between 16% and 18.5%. 13, 14 A possible explanation for the lower incidence of second malignancies in the registries registered with the SEER could be international difference in registration procedures used by various cancer registries. 20 The completeness of data in a cancer registry is determined by several factors particularly the guidelines for screening and diagnosis of cancer. Differences in these guidelines could potentially influence the reported incidence of cancer in a FIGURE 1. Kaplan-Meier analysis to analyze the effect on second primary cancers (SPCs) on overall survival in patients with renal cell carcinoma (RCC). Univariate analysis revealed that the survival of patients with RCC and one/more second primary cancers was significantly greater (151 ± 2 mo) than that of patients where RCC was the only primary cancer (111 ± 1 mo, P < 0.001 by Log Rank test). given population. 21 Furthermore, genetic differences (including polymorphisms) and differences in the environment (eg, food habits, exposure to environmental carcinogens and lifestyle) might contribute to a higher or lower risk of SPCs in a given population.
In terms of the total number, the sites with the most second primary tumors in the SEER database were in the male genital system (24% of total), digestive system (19% of total), and respiratory system (15% of total). These 3 systems together accounted for 58% of all second malignancies. Specifically, the prostate gland, colon, and the lung and bronchus were the sites in these systems with a consistent increase in risk of second malignancies in nearly all patient and treatment groups. This finding is similar to a report by Thompson et al, 14 who observed that the risk of a second malignancy in RCC patients was highest in the prostate and colon. Rabbani et al 13 also reported that the papillary type of RCC is associated with a significantly increased risk of second cancers in the prostate and bladder. Other smaller studies have reported that the most common sites for SPCs in RCC are the prostate, colon, and urinary bladder. 22, 23 Although second cancers in the bladder accounted for 6.4% of all SPCs in our study (Table 1) , the risk was significant only in patients aged 60 years or more (at time of diagnosis of either RCC or the SPC), with RCCs r5 cm in size and in patients without a history of radiation therapy (Table 3 ). There was no difference in incidence of second cancers in the bladder with either sex or race of the patient. Among hematologic malignancies, lymphomas were the most common second malignancies in RCC patients with 143 (3.8% of total) observed in the SEER population. Specifically, the risk of non-Hodgkin lymphoma was increased, being significantly elevated in those <30 years old at the time of diagnosis of RCC and within 6 months after the diagnosis of RCC in both sexes ( Supplementary Tables 1 and 2 ). Beisland et al 12 had also reported in their aforementioned study that non-Hodgkin lymphoma (together with melanoma) was the most common second malignancy in patients with an existing RCC.
The occurrence of 2 primary cancers in the same patient is, however, by itself not sufficiently strong to support the hypothesis that a common underlying mechanism may be driving both malignancies. However, if the risk of development of one malignancy in presence of the second is reciprocal (ie, presence of either malignancy as the first increases the risk of the second in the same patient), the chance that the 2 are driven by a common mechanism would be significantly increased. Using this principle of reciprocal risk, we noted that solid tumors with a mutually increased risk of occurrence (with RCC) were the skin (excluding basal and squamous cell carcinomas), urinary bladder, prostate, thyroid, and adrenal glands (Supplementary Table 8 ; Supplemental Digital Content 8, http://links.lww.com/AJCO/A12). Among the lymphatic and hematopoietic malignancies, the risk of leukemias was reciprocally increased in RCC patients. Several other studies have also reported (using the principle of reciprocal risk) that significant reciprocal associations exist between RCC and malignancy at another site. For instance, a study using data from the New South Wales Central Cancer Registry (Australia) reported that cancer of the renal parenchyma was associated with a significant increase in the risk of prostate cancer, and that the reciprocal was also true. A similar reciprocal risk relationship was reported by McCredie et al 24 for RCC and cancer of the urinary bladder. However, the enhanced risk was confined only to women. An analysis of the Danish Cancer Registry (1943 to 1980) revealed that patients with a primary malignancy in the kidney were at a significantly elevated risk of a second primary in the bladder (SIR: 7.1, 95% CI 6.0-8.4) and the reciprocal was true for patients with a primary malignancy of the bladder (SIR for SPC in the kidney being 3.2, 95% CI 2.7-3.8). 25 Although the exact mechanism for this reciprocal risk phenomenon is not known, a few possibilities can be suggested. These include a common environmental (eg, cigarette smoking and/ or alcohol are linked to cancers of the urinary system, respiratory system, oral cavity, pharynx, esophagus, pancreas, and cervix, and benzidene for RCC and bladder cancer) or genetic risk factor (cooccurrence of familial papillary carcinoma of thyroid and papillary carcinoma of the kidney linked to the chromosome locus 1q21). [25] [26] [27] Familial RCC has also been shown to increase the risk of a SPC in the urinary bladder and endocrine glands by nearly 3-fold. 28 The exact mechanism by which these factors induce oncogenic transformation at 2 separate anatomic sites, however, remains to be elucidated.
A significant observation in our analysis was a prominent increase in the risk of endocrine cancers, specifically thyroid and adrenal gland malignancies in patients with RCC. Although the exact mechanism underlying the cooccurrence of RCC with thyroid cancer is unknown, one possibility is the occurrence of common genetic alterations that drive the development of tumors at the 2 sites. Missense mutations in CHEK2, a gene encoding the human analog of the yeast checkpoint kinases Cds1 and Rad53 have, for instance, been associated with a significant increase in the risk of thyroid, prostate, colon breast, and kidney cancer. 29 In contrast, the best known condition associated with an inherited risk of clear cell carcinoma of the kidney together with cancers in the adrenal glands, is the von Hippel-Lindau syndrome, an autosomal dominant disease characterized by hemangioblastomas in the brain, spinal cord, and retina and tumors in the kidney, adrenal glands, and lymphatics. 30 Sporadic cases of RCC with adrenal malignancies are, however, quite rare, limited to a handful of case reports. 31 Future studies in patients with these inherited syndromes could help elucidate the molecular mechanism underlying the development of multiple primaries including RCC.
An important focus of oncologic research from the standpoint of public health is the impact of cancers (in this case SPCs) on the survival of patients. Once the predictors of survival are identified, these could be used to guide therapeutic interventions and surveillance strategies to improve survival. We observed that patients who had both an RCC and a SPC had a significantly longer survival than those with RCC alone (Table 4 ). However, this difference did not remain significant on multivariate analysis suggesting that, although the presence of second primaries may improve survival, they were not an independent predictor of OS in these patients. A similar observation (ie, better survival in patients with one/more SPCs) has previously been reported in a study of 80 patients with cancers of the renal pelvis. Median survival was significantly better in those patients who had a history of a prior urothelial malignancy (42 mo) compared with those in whom it was the only malignancy (19 mo). 32 Of note, RCC patients who received radiation therapy had a dramatic reduction in OS (26 ± 1 mo vs. 119 ± 0.9 mo in those who did not receive radiation). This concurs with previous reports in the literature that suggested that radiation therapy does not improve survival in patients with RCC. 33 Recent clinical trials have also not found any significant benefit with radiation therapy in RCC except in patients with brain metastasis, and even in them it has not been shown to produce a significant improvement in the progression free interval. 34, 35 It is possible that the lower survival in patients who received therapeutic radiation was due to the adverse effects of radiation itself including bone marrow depression and the resulting morbidity. Our finding of a longer OS in female RCC patients agrees with a recent study by Aron et al, which found that female patients presented with smaller tumors, which were of a lower histologic grade, compared with male patients who most often presented with regional or distant metastasis. 36 Although it is not clear how being married improved survival in RCC patients, one possible explanation is that these patients were more likely to receive emotional and psychological support that might have contributed to their longer survival.
When we examined the factors that affect survival in RCC patients with one/more second primaries (SPCs), we noted that they were very similar to those that predicted longer survival in patients with RCC alone. Thus, age <60 years at the time of diagnosis of RCC (or the second primary), white or nonblack race, married status, localized and well-differentiated primary renal tumors arising from the left side, and absence of a history of therapeutic radiation were predictors of a longer survival on univariate analysis ( Table 6 ). An additional factor that specifically predicted a better survival in patients with second primaries was a longer interval between diagnosis of RCC and the second primary (patients diagnosed with a second primary 5 y or later after the diagnosis of RCC had the longest OS). Upon multivariate analysis, time elapsed between the diagnosis of RCC and the second primary was an independent predictor of survival with, patients diagnosed with a second malignancy <1 year after being diagnosed with RCC having a significantly poorer OS compared with those diagnosed >1 year later (hazards ratio 2.1, P < 0.001, Table 7 ). To validate the results of our multivariate survival analysis in patients with second primaries, we searched the literature for actual case studies on survival in patients with RCC and a second malignancy. Studies wherein a second primary was diagnosed <1 month after diagnosis of the RCC were excluded. We identified a study by Choueiri et al, wherein they had reported a series of 4 patients with RCC who subsequently developed multiple myeloma (MM) (summarized in Supplementary Table 9 ; Supplemental Digital Content 9, http://links.lww.com/AJCO/A13). 37 Of the 4 patients, the shortest survival time (9 mo from the time of diagnosis of RCC) was noted for a 66-year-old male patient (patient 3) who was diagnosed with MM 1 month after being diagnosed with RCC, whereas the longest survival (11 y) was observed for a 61-year-old male patient diagnosed with MM 108 months after being diagnosed with RCC (patient 1). On the basis of our multivariate analysis, patient 3 would be expected to have the shortest survival as he had 2 adverse prognostic factors-age >60 years at presentation with RCC and time elapsed between the diagnosis of RCC and the second primary <1 month. Patient 1 with 1 adverse factor (age >60 y) would be predicted to have a longer survival. A comparison of the predicted and actual survival for the 4 patients in this series is presented in Supplementary Table 9 (Supplemental Digital Content 9, http://links.lww.com/AJCO/A13).
A key observation in our analysis was the significantly higher risk of developing a SPC (nearly 5-fold) in younger patients (age <30 y at the time of diagnosis of RCC) than in older patients with an antecedent RCC ( Table 1 ). Hartley et al 38 had reported in a series of 218 patients diagnosed with renal tumors in childhood that the excess risk of developing a second malignancy was significantly higher than expected (N = 8, SIR: 14.7). The investigators also suggested that development of bony exostoses might predict the development of a subsequent malignancy in patients with childhood renal tumors. It is possible that the elevated risk of SPCs in younger patients observed in our study could be at least partly due to an inherited predisposition to develop multiple tumors. However, this would need to be confirmed by detailed genetic analysis in a separate study.
In conclusion, we have conducted the first comprehensive analysis of SPCs in patients with RCC as the first primary malignancy using data from the SEER database. We have also examined the prognostic significance of factors influencing OS of patients with RCC with/without SPCs. Our results suggest that several patient-related, tumor-related, and treatment-related factors can affect the risk of SPCs at specific sites and influence the prognosis of RCC patients. By comparing our findings with published studies, we have demonstrated the correlation of database based studies with incidence and prognosis of RCC patients in actual hospital-based settings. The results from the study have important implications in investigating the mechanisms underlying the occurrence of multiple primary tumors and in planning surveillance strategies for patients with newly diagnosed RCC.
